Dementia - an innovative treatment with Bacopa monnieri Linn

A Phase II study on the effect of Brahmi (Bacopa monnieri Linn) in various types and grades of dementia by comparing the effect of the drug on the participants using the Global Deterioration Scale (GDS) and Standardized Mini-Mental State Examination (SMMSE)

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN12595633

Enrollment

Registered

2019-07-22

Start date

2019-08-01

Completion date

Unknown

Last updated

2020-05-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Dementia Mental and Behavioural Disorders Unspecified dementia

Interventions

Every patient will be administered an extract of Brahmi (Himalaya) at a dose of 250 mg tablets twice daily orally for three months. The GDS and SMMSE will be determined before the start of the treatme

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Aged 18 years and over 2. Diagnosis of dementia

Exclusion criteria

Exclusion criteria: 1. History of intolerance or allergy to Brahmi 2. Type 1 diabetes mellitus 3. Pregnancy

Design outcomes

Primary

Measure	Time frame
Dementia progression measured using the Global Deterioration Scale (GDS) and Standardized Mini-Mental State Examination (SMMSE) at baseline and at the end of 3 months	—

Secondary

Measure	Time frame
Age-related falls measured through self-reporting by patients and/or their attendants at baseline and after 1 and 3 months	—

Countries

India

Contacts

Public ContactAjay Kumar Mishra

drakm1969@gmail.com+91 (0)9431857475

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026